Pasithea

Investor Relations

Latest Financial Results

Q3 2021

Quarter Ended Sep 30, 2021

Email Alerts

Sign up today and receive company updates straight to your inbox.

Sign up today

Company Overview

We are a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.

Our secondary operations are focused on establishing anti-depression clinics across the United Kingdom and providing business support services to similar entities in the United States and using psychiatric assessment combined with physician/medical providers to administer intravenous infusions of ketamine.

IR Contacts

Company

Pasithea Therapeutics Corp.
1111 Lincoln Road
Suite 500
Miami Beach, FL 33139
T: 305-493-8080
info@pasithea.com

Investor Relations

In-Site Communications, Inc
Lisa Carlton-Wilson
Founder
T: 917-543-9932
lwilson@insitecony.com

Transfer Agent

VStock Transfer, LLC
Pasquale Preziosa Jr
Director of On-Boarding and Corporate Actions
18 Lafayette Place
Woodmere, New York 11598
T: 212-828-8436
https://www.VStockTransfer.com

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.